Patent · US Active

Angiopoietin 2, VEGF dual antagonists

US11059885B2 · kind B2 · utility

3Cited by
5References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateApr 10, 2019
Grant dateJul 13, 2021
Priority date—
Expiry dateApr 10, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/32
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present disclosure relates to fusion molecules and chimeric molecules which comprise two components: an Ang-2 antagonist peptide linked to a VEGF-binding moiety. Further disclosed are methods of using said chimeric molecules to treat a patient cancer, proliferative retinopathy, neovascular glaucoma, macular edema, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.